OBJECTIVES: Individuals with disabilities are at greater risk of hospitalization than the general population. We examined 10-year trends in potentially preventable hospitalizations (PPH) in Korea, comparing individuals with and without disabilities and assessing age-specific patterns. METHODS: Using National Health Information Database claims data (2010–2019), we established a fixed cohort of newly registered individuals with disabilities and control subjects statistically matched (1:1.5) at baseline. Annual PPH rates among patients with each condition were calculated and age- and sex-standardized according to Organization for Economic Cooperation and Development Health Care Quality Indicators definitions. Trends and annual percent changes (APCs) were analyzed by disability status and age group (non-older: 30–64; older adults: ≥65 years). RESULTS: Between 2010 and 2019, PPH rates declined significantly in both groups. Among individuals with disabilities, the steepest decline was observed for hypertension (APC, −15.7%; 95% confidence interval [CI], −17.7 to −13.7), whereas congestive heart failure showed the largest reduction among individuals without disabilities (APC, −7.8%; 95% CI, −10.8 to −4.7). Declines were generally greater among non-older adults aged 30–64 years, regardless of disability status. The disparity between disability and non-disability groups narrowed over the decade, primarily due to larger improvements among non-older adults. Older adults with disabilities consistently exhibited the highest PPH rates for most conditions, whereas younger individuals with disabilities had the highest rates for diabetes. CONCLUSIONS PPH rates declined over the decade among both individuals with and without disabilities, particularly for hypertension and among non-older adults. However, older adults with disabilities remain at elevated risk, underscoring the need for targeted strategies to improve access to community-based primary care.

We updated the Korean Society of Gynecologic Oncology (KSGO) practice guideline for the management of ovarian cancer as version 5.1. The ovarian cancer guideline team of the KSGO published announced the fifth version (version 5.0) of its clinical practice guidelines for the management of ovarian cancer in December 2023. In version 5.0, the selection of the key questions and the systematic reviews were based on the data available up to December 2022.Therefore, we updated the guidelines version 5.0 with newly accumulated clinical data and added 5 new key questions reflecting the latest insights in the field of ovarian cancer between 2023 and 2024. For each question, recommendation was provided together with corresponding level of evidence and grade of recommendation, all established through expert consensus.

We updated the Korean Society of Gynecologic Oncology (KSGO) practice guideline for the management of ovarian cancer as version 5.1. The ovarian cancer guideline team of the KSGO published announced the fifth version (version 5.0) of its clinical practice guidelines for the management of ovarian cancer in December 2023. In version 5.0, the selection of the key questions and the systematic reviews were based on the data available up to December 2022.Therefore, we updated the guidelines version 5.0 with newly accumulated clinical data and added 5 new key questions reflecting the latest insights in the field of ovarian cancer between 2023 and 2024. For each question, recommendation was provided together with corresponding level of evidence and grade of recommendation, all established through expert consensus.

We updated the Korean Society of Gynecologic Oncology (KSGO) practice guideline for the management of ovarian cancer as version 5.1. The ovarian cancer guideline team of the KSGO published announced the fifth version (version 5.0) of its clinical practice guidelines for the management of ovarian cancer in December 2023. In version 5.0, the selection of the key questions and the systematic reviews were based on the data available up to December 2022.Therefore, we updated the guidelines version 5.0 with newly accumulated clinical data and added 5 new key questions reflecting the latest insights in the field of ovarian cancer between 2023 and 2024. For each question, recommendation was provided together with corresponding level of evidence and grade of recommendation, all established through expert consensus.

Purpose: Papillary thyroid carcinoma (PTC) is the most prevalent endocrine malignancy, and the global incidence has been steadily increasing over the years. Although PTC generally exhibits favorable prognosis, a subset of patients experiences aggressive progression and increased mortality. Current prognostic approaches, reliant on clinic-pathological factors, have limitations, underscoring the need for innovative biomarkers. MicroRNAs (miRs) have emerged as promising candidates due to their roles in cellular processes and cancer progression. Among them, the present study investigated the role of miR-18b in PTC, exploring its potential as a prognostic biomarker. Methods: Utilizing PTC cell lines (TPC1, K1), we examined miR-18b expression and its regulatory effects. The present study used web-based tools to predict the target of miR-18b and to investigate the prognostic impact of miR-18b on thyroid cancer. Results: Through a series of cell proliferation, invasion assay, gap closure, and colony formation assays, we identified that miR-18b suppresses PTC aggressiveness. Dual-luciferase assays confirmed that miR-18b directly targeted the 3’-untranslated region of CDK2 and suppressed the expression of CDK2. In addition, miR-18b significantly attenuates the interaction between cyclin A or cyclin E with cyclin-dependent kinase 2 according to co-immunoprecipitation assay.Western blotting of cell cycle proteins and flow cytometry revealed miR-18b–induced cell cycle arrest and apoptosis. Conclusion Our findings underscore miR-18b’s potential as a biomarker for predicting the prognosis of PTC and suggest that it functions through direct regulation of CDK2, influencing cell cycle dynamics. This study not only enhances our understanding of miR-18b in thyroid cancer but also highlights its potential in refining prognostic evaluations and therapeutic strategies.

Objective: To identify proteins regulated by baicalin in a rat model of ischemic stroke. Methods: Adult male Sprague Dawley rats underwent middle cerebral artery occlusion (MCAO) or sham surgery and received intraperitoneal baicalin (100 mg/kg) or vehicle 1 h before surgery. Neurobehavioral assessments were performed 24 h after MCAO, and cerebral cortex tissues were collected. Cortical damage was evaluated using 2,3,5-triphenyltetrazolium chloride staining and hematoxylin-eosin staining. Protein expression changes between groups were assessed by liquid chromatography-tandem mass spectrometry, and selected targets were validated by reverse transcription-polymerase chain reaction. Results: MCAO induced marked neurological deficits, infarction, and histopathological damage, all of which were significantly attenuated by baicalin treatment. MCAO decreased adenylate cyclase type 1 and solute carrier family 25 member 12 levels, and baicalin mitigated these reductions. Baicalin also reduced MCAO-induced increases in C-reactive protein and apolipoprotein C-II, as well as alpha-1 microglobulin, murinoglobulin, and hemoglobin subunit B, proteins associated with inflammation, lipid metabolism, mitochondrial function, and cellular injury. Conclusions and Relevance: Baicalin exerts neuroprotective effects in cerebral ischemia by modulating proteins involved in energy metabolism, myelination, and neuroinflammation.These findings support baicalin as a promising therapeutic candidate in experimental stroke models.

Background: The prevalence of service-oriented roles in the contemporary workplace has led to an increased demand foremployees to engage in emotional labor to navigate the challenges of a service-oriented economy. This study aimed to examine the association between emotional labor and work absence due to dental treatment and assess the role of various factors between emotional labor and work absence due to dental treatment. Methods: Four hundred and eighty-three workers participated in this survey. Work absence was an outcome variable, andemotional labor was an independent variable. Logistic regression analyses were performed to find the association between emotional labor and work absence due to dental treatment controlling for age, sex, and education. The impacts of mediators (work type, employment type, and stress) were also assessed. Furthermore, the association between emotional labor and absenteeism due to dental treatment was assessed according to the stress level. Results: Emotional labor was associated with a 1.75 times higher risk of absenteeism due to dental treatment (95% confidenceinterval 1.04∼2.83) across adjusted models among Korean workers. The impact of stress was the highest among the mediators.Despite the non-statistical significance of the results, it was observed that elevated stress levels were correlated with increased dental absenteeism due to emotional labor. Conclusion The findings of this study indicate that the performance of emotional labor is associated with an increased prevalenceof absenteeism due to dental treatment. High stress levels may result in even higher rates of absenteeism among Korean workers.

Since the latest practice guidelines for ovarian cancer were developed by the Korean Society of Gynecologic Oncology (KSGO) in 2021, many studies have examined the efficacy and safety of various treatments for epithelial ovarian cancer (EOC). Therefore, the need to develop recommendations for EOC treatments has been raised. This study searched the literature using 4 key items and the Population, Intervention, Comparison, and Outcome: the efficacy and safety of poly-ADP ribose polymerase inhibitors in newly diagnosed advanced EOC; the efficacy and safety of intraperitoneal plus intravenous chemotherapy in optimally debulked advanced EOC; the efficacy and safety of secondary cytoreductive surgery in platinumsensitive recurrent ovarian cancer; and the efficacy and safety of the addition of bevacizumab to platinum-based chemotherapy in first platinum-sensitive recurrent EOC patients who received prior bevacizumab. The evidence for these recommendations, according to each key question, was evaluated using a systematic review and meta-analysis. The committee of ovarian cancer of the KSGO developed updated guidelines for treatments of EOC.

Background/Aims: To determine the association between evolutionary changes in metabolic dysfunction-associated steatotic liver disease (MASLD) status and the risk of hepatocellular carcinoma (HCC) in a nationwide population-based cohort. Methods: Information on study participants was derived from the Korea National Health Insurance Service database. The study population consisted of 5,080,410 participants who underwent two consecutive biennial health screenings between 2009 and 2012. All participants were followed up until HCC, death, or 31 December 2020. The association of evolutionary changes in MASLD status, as assessed by the fatty liver index and cardiometabolic risk factors, including persistent non-MASLD, resolved MASLD, incident MASLD, and persistent MASLD, with HCC risk was evaluated using multivariable-adjusted Cox proportional hazards regression. Results: Among the 5,080,410 participants with 39,910,331 person-years of follow-up, 4,801 participants developed HCC. The incidence of HCC in participants with resolved, incident, and persistent MASLD was approximately 2.2-, 2.3-, and 4.7-fold higher, respectively, than that in those with persistent non-MASLD among the Korean adult population. When stratifying the participants according to the evolutionary change in MASLD status, persistent (adjusted hazard ratio [aHR], 2.94; 95% confidence interval [CI], 2.68–3.21; P<0.001), incident (aHR, 1.85; 95% CI, 1.63–2.10; P<0.001), and resolved MASLD (aHR, 1.33; 95% CI, 1.18–1.50; P<0.001) had an increased risk of HCC compared to persistent non-MASLD. Conclusions The evolutionary changes in MASLD were associated with the differential risk of HCC independent of metabolic risk factors and concomitant medications, providing additional information on the risk of HCC stratification in patients with MASLD.

Background: The prevalence of service-oriented roles in the contemporary workplace has led to an increased demand foremployees to engage in emotional labor to navigate the challenges of a service-oriented economy. This study aimed to examine the association between emotional labor and work absence due to dental treatment and assess the role of various factors between emotional labor and work absence due to dental treatment. Methods: Four hundred and eighty-three workers participated in this survey. Work absence was an outcome variable, andemotional labor was an independent variable. Logistic regression analyses were performed to find the association between emotional labor and work absence due to dental treatment controlling for age, sex, and education. The impacts of mediators (work type, employment type, and stress) were also assessed. Furthermore, the association between emotional labor and absenteeism due to dental treatment was assessed according to the stress level. Results: Emotional labor was associated with a 1.75 times higher risk of absenteeism due to dental treatment (95% confidenceinterval 1.04∼2.83) across adjusted models among Korean workers. The impact of stress was the highest among the mediators.Despite the non-statistical significance of the results, it was observed that elevated stress levels were correlated with increased dental absenteeism due to emotional labor. Conclusion The findings of this study indicate that the performance of emotional labor is associated with an increased prevalenceof absenteeism due to dental treatment. High stress levels may result in even higher rates of absenteeism among Korean workers.